Starling Oncology, Inc. (STLN)
Starling Oncology, Inc. operates in the Medical - Care Facilities industry of the Healthcare sector, headquartered in Cerritos, CA, US. The stock last traded at $3.00, down 5.66% on the session, giving a market capitalisation of $306.0M. On trailing twelve-month figures it carries a trailing P/E of -10.34, a net margin of -5.7%. Its beta of 0.42 implies it has historically moved less than the broad market.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.